Articles tagged with Alzheimer Disease
A new study from Harvard University reveals that brain systems in older adults are less coordinated than those in younger individuals, even if there is no Alzheimer's disease present. This decline affects the way different brain regions communicate and process information.
New research by University of Illinois at Chicago chemists identifies intermediate step in amyloid plaque formation as a toxic culprit. Tiny spheres averaging 20 nanometers assemble into sheet-like structures comparable to fibrils, making them more than 10 times poisonous.
A new study found that hypertension significantly reduces cerebral blood flow in adults with Alzheimer's disease, increasing its vulnerability to the effects of the disease. Good vascular health is crucial for brain health, and detecting and treating hypertension can help prevent or slow cognitive decline.
A recent study has found that progesterone has limited benefits for mice with Alzheimer's symptoms, but inhibits some of estrogen's beneficial effects when taken together. The study suggests that the constant daily dosage of progesterone may be antagonizing its potential benefits.
Researchers have discovered a potential therapeutic approach to prevent the accumulation of toxic protein plaques in the brain, which are a hallmark of Alzheimer's disease. The study suggests that binding cystatin C to soluble amyloid beta prevents its aggregation into insoluble plaques.
A study published in Neurology found that Latinos and African Americans with Alzheimer's disease lived significantly longer than white individuals. The study involved nearly 31,000 participants and adjusted for various factors, including education level and age when symptoms began.
A diet high in fish, omega-3 oils, and fruits/vegetables can significantly reduce the risk of dementia. The study found a 60% lower risk for those consuming omega-3 rich oils, while a 30% lower risk was seen for those eating fruits and veggies daily.
A new research study from Oklahoma Medical Research Foundation demonstrates that immunization could blunt or prevent Alzheimer's disease by targeting the build-up of protein plaques. The vaccinated mice showed a significant reduction in plaque accumulation and improved cognitive performance compared to control mice.
Scientists have found a specific way in which copper contributes to the disease process in Alzheimer's. Copper damages the molecule LRP, which normally escorts out amyloid beta from the brain, leading to increased levels of the toxic substance in the brains of people with Alzheimer's.
A recent study found that individuals with an affected mother have reduced brain metabolism in certain regions, similar to Alzheimer's patients. This suggests a possible link between maternal transmission and increased disease risk.
Research presented at Neuroscience 2007 found that Concord grape juice and Cabernet Sauvignon polyphenols can slow beta-amyloid neuropathology. The study suggests a potential protective role for non-alcoholic, polyphenol-rich Concord grape juice in maintaining long-term cognitive health.
Researchers found that people with high blood pressure or atrial fibrillation progress more rapidly with Alzheimer's disease. Treating these conditions may also slow memory loss in AD patients.
A new study by OHSU researchers has found that children carrying the apoE4 gene already exhibit reduced cognitive function. They used a virtual reality test to assess spatial learning and memory in 7- to 10-year-olds with and without the gene.
A study published in Neurology found that people with high blood pressure and chest pains lose their memories faster than those without these conditions. Vascular factors such as high blood pressure and irregular heartbeats were associated with a more rapid decline in cognitive tests.
A PET scan significantly improves the accuracy of diagnosing Alzheimer's disease and frontotemporal dementia (FTD) by measuring brain sugar uptake. The study found that FDG-PET scans correctly diagnosed FTD and Alzheimer's in almost 90% of cases, increasing accuracy by 14%.
Duke researchers identified a new brain marker that may help predict future Alzheimer's disease by tracking deactivation of the posteromedial cortex. A third of individuals with mild cognitive impairment converted to Alzheimer's in three years, with fMRI scans predicting this progression.
A new study found that approximately 13.9 percent of the population aged 71 and older have some form of dementia, with Alzheimer's disease being the most common cause. The prevalence of dementia increased dramatically with age, from five percent of those aged 71 to 79 to 37.4 percent of those age 90 and older.
A new study reveals that the intrinsic tendency of amyloid peptide Aß to aggregate determines its pathogenicity in Alzheimer disease. The researchers used a fruit fly model to identify the determinants of Aß's toxicity, finding a clear correlation between aggregation propensity and disease progression.
Researchers found that valsartan, an antihypertensive medication, reduces the accumulation of beta-amyloid protein in mouse brains, a key feature of Alzheimer's. The study suggests that treating high blood pressure with certain medications may help prevent or slow the progression of AD.
Researchers identified 7 anti-hypertensive drugs that significantly prevent beta-amyloid production, a key mechanism in Alzheimer's disease. These drugs, including Valsartan and Propranolol HCI, showed promise in preventing cognitive deterioration and memory loss in mice with Alzheimer's disease.
A team of experts is conducting a genome-wide association scanning study to analyze DNA samples from 14,000 people with late-onset Alzheimer's disease and healthy controls. This study aims to identify common genetic variations that increase the risk of the disease, providing valuable insights into its causes.
Researchers have made significant breakthroughs in Alzheimer's disease research, identifying A
Researchers at Stanford University School of Medicine have developed a blood test that can identify changes in proteins in blood plasma, indicating an increased risk of developing Alzheimer's disease. The test showed 90% accuracy in matching clinical diagnoses and predicting the onset of the disease two to six years in advance.
Researchers used a novel 3D mapping technique to analyze MRI data from Alzheimer's patients and those with mild cognitive impairment (MCI). The study found progressive brain atrophy in both groups, but MCI patients showed more cortical damage characteristic of Alzheimer's. This innovative method outperforms existing 3D imaging techniques.
Researchers at Saint Louis University have found an injectable antibody that can reverse learning problems in mice with an animal version of Alzheimer's disease. The antibody, part of the IgM class, targets amyloid beta protein and prevents it from becoming toxic.
NCCAM has added three new Centers of Excellence for Research on Complementary and Alternative Medicine (CAM), focusing on the biological effects of plant-derived compounds on various health conditions. The centers will investigate mechanisms and effects of compounds like curcumin, resveratrol, and grape polyphenols in preventing or tre...
Researchers at Washington University School of Medicine found a molecular connection between amyloid-beta production and cholesterol levels in the brain, linking early- and late-onset Alzheimer's. This discovery suggests that abnormal brain cholesterol metabolism may play a role in the disease.
Researchers have discovered a biological link between amyloid precursor protein and a gene variant linked to late-onset Alzheimer’s disease. This finding may lead to new therapeutic strategies for treating the devastating disease.
Conscientious individuals have a lower risk of developing Alzheimer's disease and experiencing cognitive decline. A study of over 997 older adults found that those with high levels of conscientiousness had an 89% lower risk of developing the disease.
A study published in Neurology found that individuals with lower levels of education are at a higher risk of developing dementia and Alzheimer's disease. Those with higher levels of education had an 80-percent lower risk, possibly due to a greater cognitive reserve.
Scientists at Northwestern University have discovered that a toxic protein in the brains of individuals with Alzheimer's removes insulin receptors from nerve cells, rendering those neurons insulin resistant. This finding sheds light on the emerging idea of Alzheimer's being a type 3 diabetes.
Apolipoprotein E (APOE) genetic risk factor for Alzheimer's disease will be examined in a five-year project testing healthy adults aged 18-75. The study aims to identify markers sensitive to APOE, potentially leading to earlier detection and prevention of the disease.
Researchers have identified a new brain marker that may help diagnose Alzheimer's disease earlier, using fMRI to monitor changes in brain activation and deactivation. The study found that impaired deactivation in the posteromedial cortices was closely related to memory impairment and neuropsychological testing scores.
A six-year study involving 3,885 participants found no significant changes in memory function among overweight and obese individuals. In contrast, those who were underweight experienced more cognitive decline over time. The study suggests that being overweight or obese in old age may not be a risk factor for memory problems.
A national survey found racial differences in knowledge and beliefs about Alzheimer's disease, with blacks and Hispanics more hopeful about research advances and reporting lifestyle changes to reduce risk. Despite increased knowledge over the past two decades, misconceptions remain among large segments of the population.
Researchers propose a new way to diagnose Alzheimer's disease in its earliest stages, allowing for earlier treatment and potential prevention through vaccines or targeted drug therapies. The new guidelines focus on advanced brain imaging techniques and biomarkers, enabling early detection of the disease.
A Mediterranean diet was found to reduce mortality in Alzheimer's patients by an average of 1.3 years for moderate adherence and four years for strict following. The study followed 192 people with Alzheimer's disease in New York for an average of four and a half years.
Researchers discovered 'silent' seizures in mice with Alzheimer's disease, which may be related to cellular changes involving amyloid beta protein accumulations. These seizures could contribute to episodes of confusion in advanced Alzheimer's patients.
A study published in Neuron found a link between the toxic brain protein Aâ peptide and neuronal overexcitation, leading to compensatory rewiring of brain circuitry. This overexcitation can contribute to cognitive deficits in Alzheimer's disease. Researchers suggest blocking this overexcitation may prevent such neurological deficits.
Researchers found that high levels of Amyloid-beta induce seizure-like activity in learning and memory centers, leading to cognitive impairments. The study provides new insights into the development of Alzheimer-related cognitive decline and potential therapeutic strategies.
A new study led by Dr. Mary S. Mittelman found that enhanced counseling and support for Alzheimer's caregivers preserves their physical health and eases depression. The intervention improved self-reported health within four months of enrollment, lasting over a year.
A new study found a strong link between reduced levels of LR11 in the brain tissue of individuals with mild cognitive impairment (MCI) and the onset of Alzheimer's disease. The findings suggest that LR11 may be a biomarker for predicting disease progression and a potential therapeutic target.
A recent study published in Neurology found that smokers are 50% more likely to develop dementia than nonsmokers or past smokers. The study suggests that smoking increases the risk of dementia through mechanisms such as oxidative stress, which can damage cells in blood vessels and lead to hardening of the arteries.
Researchers found that statin treatment may curb Alzheimer's brain changes, with a study comparing brain scans of people who took statins to those who did not. The study, published in Neurology, included 110 Group Health members aged 65-79 and provided the first direct evidence of statin's potential protective effect on the brain.
A new study found that high stress levels contribute to memory loss among individuals at risk for developing Alzheimer's disease. Those with the APOE-å4 gene variant and high cortisol levels showed significant memory impairment, suggesting a link between chronic stress and cognitive decline.
Researchers have developed a new test that can diagnose common brain diseases like Alzheimer's and schizophrenia with high accuracy. By analyzing tiny magnetic fields produced by neuron activity, the test can identify patterns associated with these debilitating diseases.
Researchers identified a brain network in the frontal lobe associated with cognitive reserve, which builds through mentally-stimulating activities and provides protection against Alzheimer's disease. The study found that participants with higher levels of cognitive reserve could activate this network while working on difficult tasks.
Recent mouse breeds designed to mimic Alzheimer's disease symptoms may not accurately reflect the human condition, according to a new study. The researchers suggest using alternative mouse breeds with only APP mutations to improve the accuracy of drug testing.
Researchers discovered that increasing the body's ability to absorb amyloid-beta in the blood leads to a decrease in brain levels, halting symptoms. A modified version of the sLRP protein showed promise in mice and humans, promising a new treatment option for Alzheimer's.
Six researchers will receive $60,000 awards to investigate biological, genetic, and environmental factors associated with Alzheimer's. The study aims to identify new biomarkers and therapeutic targets for the disease, which affects an estimated 26 million people worldwide.
A UCF team led by Kiminobu Sugaya has discovered a compound, phenserine, that reduces plaque buildup in Alzheimer's disease. This combination with stem cell transplantation triggers neuron regeneration, offering hope for patients. Further research, including clinical trials, is needed to confirm its effectiveness.
A team of researchers defined how metal ions bind to amyloid fibrils in the brain, appearing toxic to neurons. The findings suggest that only one way of binding appears toxic, while others may be harmless.
Researchers have found a clear link between Alzheimer's disease and glaucoma, with key proteins implicated in both conditions. Novel drugs targeting these proteins may be used to treat glaucoma, opening up new avenues for treatment beyond intraocular pressure control.
A six-month study found that a medication initially used for mild to moderate Alzheimer’s disease improved memory and global function in people with severe Alzheimer’s disease. Cognitive tests showed stabilization or improvement in 63% of participants taking the drug compared to 39% on placebo.
Researchers isolated bisdemethoxycurcumin, which boosts macrophages to clear amyloid beta plaques found in Alzheimer's disease. The study identified key genes involved in this process, offering a new treatment approach that targets the innate immune system.
The new criteria focus on a clinical core of early and significant episodic memory impairment, incorporating biomarker-based tests. Validation studies are necessary to optimize sensitivity, specificity, and accuracy.
Researchers have identified a protective role for normal prion proteins in preventing the formation of beta-amyloid plaques in the brain, a hallmark of Alzheimer's disease. High levels of PrPc reduced beta amyloid formation, while low or absent levels allowed it to return.
Researchers found that older adults with difficulty identifying common odors were more likely to develop mild cognitive impairment and Alzheimer's disease. Olfactory dysfunction was associated with lower cognitive scores and a faster decline in memory, supporting the idea that smell identification may be an early indicator of Alzheimer's.
A study published by the American Academy of Neurology found that older adults with high levels of cognitive activity were 2.6 times less likely to develop dementia and Alzheimer's disease. Frequent cognitive stimulation during old age was associated with reduced risk of mild cognitive impairment and slower decline in cognitive function.
A new Alzheimer's treatment, CTS-21166, designed by a Purdue University researcher has begun human clinical trials. The experimental drug is a disease-modifying therapy that could prevent and reverse the disease by intercepting and disabling key enzymes.